<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01165645</url>
  </required_header>
  <id_info>
    <org_study_id>MC1083</org_study_id>
    <secondary_id>NCI-2010-00880</secondary_id>
    <secondary_id>MC1083</secondary_id>
    <secondary_id>08-006246</secondary_id>
    <secondary_id>21096</secondary_id>
    <nct_id>NCT01165645</nct_id>
  </id_info>
  <brief_title>Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma</brief_title>
  <official_title>Lopinavir/Ritonavir as an Immunomodulator to Enhance Vaccine Responsiveness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: HIV protease inhibitors, including Lopinavir/Ritonavir have intrinsic
      anti-apoptotic properties in addition to their anti-viral effect on HIV. This anti-apoptotic
      effect may boost the immune system to help the body create a better immune response to
      vaccines. PURPOSE: This randomized clinical trial studies giving lopinavir and ritonavir
      together in improving immune response to vaccines in patients with complete remission
      following a bone marrow transplant for Hodgkin lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES: I. Compare TREC positive recent thymic emigrants, and naive CD4+ and CD8+
      T cell numbers between treatment groups. SECONDARY OBJECTIVES: I. Compare post-vaccination
      anti-rabies antibody titers between treatment groups. II. Compare post-vaccination cytokine
      levels, including IL1, IL2, IL4, IL6, IL7, IL8, IL10, IL12, INFgamma, TNFalpha, between
      treatment groups. III. Compare post-vaccination anti-rabies ELISPOT reaction between
      treatment groups. OUTLINE: Patients are randomized to 1 of 2 treatment arms. Arm I: Patients
      receive oral lopinavir and oral ritonavir twice daily for 28 days in the absence of disease
      progression or unacceptable toxicity. Arm II: Patients receive no therapy. All patients then
      receive a neo-antigen rabies vaccine.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    no patients enrolled
  </why_stopped>
  <start_date>November 2010</start_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of TREC positive recent thymic emigrants, and naive CD4+ and CD8+ T cell numbers between treatment groups</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of post-vaccination anti-rabies antibody titers between treatment groups</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of post-vaccination cytokine levels, including IL1, IL2, IL4, IL6, IL7, IL8, IL10, IL12, INFgamma, TNFalpha, between treatment groups</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of post-vaccination anti-rabies ELISPOT reaction between treatment groups</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Stage I Adult Hodgkin Lymphoma</condition>
  <condition>Stage II Adult Hodgkin Lymphoma</condition>
  <condition>Stage III Adult Hodgkin Lymphoma</condition>
  <condition>Stage IV Adult Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral lopinavir and ritonavir twice daily for 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients receive no therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lopinavir</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>ABT-378/r</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Norvir</other_name>
    <other_name>RIT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>PCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>enzyme-linked immunosorbent assay</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>ELISA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects who are in complete remission at Day +100 after a bone marrow
             transplant for Hodgkins Lymphoma

          -  Normal AST or ALT, serum creatinine and 12-lead electrocardiogram within the previous
             6 months

          -  Females of childbearing potential must have negative beta-HCG (urine or plasma) within
             the last month and agree to effective contraception during the course of the study

          -  Willingness and ability to give informed consent

          -  Willingness and ability to take pills twice a day for 28 days

        Exclusion Criteria:

          -  Known HIV positive

          -  Screening ALT or AST greater than 3X upper limit of normal

          -  Baseline QTc greater than 500 msec

          -  Current treatment with immunosuppressive agent (systemic glucocorticoid, cyclosporine,
             mycophenolate, azathioprine, sirolimus, Rituximab, infliximab, adalimumab)

          -  Current treatment with any of the following: cisapride, ergot derivatives, amiodarone,
             quinidine, terfenadine, astemizole, rifampin/rifabutin, carbamazepine, phenobarbital,
             sildenafil, St. John's wort, azithromycin, carbamazepine, HIV anti-virals, methadone,
             pimozide, phenytoin, sedative hypnotics (midazolam, triazolam), HMG-CoA reductase
             inhibitors (lovastatin, simvastatin, atorvastatin)

          -  Active malignancy requiring chemotherapy or radiation

          -  Baseline creatinine of &gt; 2.0

          -  Active infection requiring systemic anti-infective agent (excluding prophylactic
             antibiotics)

          -  Hypersensitivity to processed bovine gelatin, chicken protein, neomycin, amphotericin
             B or chlortetracycline

          -  Subject must not be on medications that interact with the metabolism of protease
             inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stacey Rizza, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2010</study_first_submitted>
  <study_first_submitted_qc>July 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2010</study_first_posted>
  <last_update_submitted>June 3, 2016</last_update_submitted>
  <last_update_submitted_qc>June 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2016</last_update_posted>
  <responsible_party>
    <name_title>Stacey A Rizza, M.D.</name_title>
    <organization>Mayo Clinic Cancer Center</organization>
  </responsible_party>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

